Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Males, Antioxidants, and Infertility Trial

ClinicalTrials.gov ID: NCT02421887

Public ClinicalTrials.gov record NCT02421887. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Males, Antioxidants, and Infertility (MOXI) Trial

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of the Males, Antioxidants, and Infertility (MOXI) Trial is to examine whether treatment of infertile males with an antioxidant formulation improves male fertility. The central hypothesis is that treatment of infertile males with antioxidants will improve sperm structure and function, resulting in higher fertilization rates and improved embryo development, leading to higher pregnancy and live birth rates. Findings from this research will be significant in that they will likely lead to an effective, non-hormonal treatment modality for male infertility. An effective treatment for men would also reduce the treatment burden on the female partner, lower costs, and provide effective alternatives to couples with religious or ethical contraindications to ART (Assisted Reproductive Technology). If antioxidants do not improve pregnancy rates, but do improve sperm motility and DNA integrity, they could allow for couples with male factor infertility to use less intensive therapies such as intrauterine insemination. Male fertility specialists currently prescribe antioxidants based on the limited data supporting their use. A negative finding, lack of any benefit, would also alter current treatment of infertile males.

Study identification

NCT ID
NCT02421887
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Yale University
Other
Enrollment
171 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2015
Primary completion
Jun 10, 2018
Completion
Nov 30, 2018
Last update posted
Sep 3, 2019

2015 – 2018

United States locations

U.S. sites
10
U.S. states
6
U.S. cities
10
Facility City State ZIP Site status
Keck School of Medicine of University of Southern California Los Angeles California 90089
University of California San Francisco San Francisco California 94115
Stanford University Sunnyvale California 94087
Augusta University Augusta Georgia 30912
Wayne State University Southfield Michigan 48034
University of North Carolina Chapel Hill North Carolina 27599
Carolinas Medical Center - Women's Institute Charlotte North Carolina 28204
University of Oklahoma Oklahoma City Oklahoma 73104
Pennsylvania State University Hershey Pennsylvania 17033
University of Pennsylvania Philadelphia Pennsylvania 19104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02421887, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 3, 2019 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02421887 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →